Accelerate Drug Development with Ultrafast Functional Interaction Mapping and Prediction
We profile millions of cell-cell interactions by functional response at the single cell level to screen for therapeutic agents. We combine ultrafast single cell-cell interaction mapping with proprietary AI models to identify novel targets and quickly build more effective and safer drugs to treat cancer and autoimmune diseases.
Powered by Proprietary Ultrafast Screening Platform and AI Models
Our proprietary TCELERATORTM platform enables us to functionally and dynamically profile millions of single cell interactions at the same time, finding rare populations that are like needles in a haystack. TCELERATORTM allows us to screen for any kind of immune modulating agent by its specific function. This precision platform is combined with proprietary AI models to yield a more comprehensive yet much faster way for drug development, leading to safer and more effective drugs.
Centered around people
We believe that people are the key that drives scientific and organizational successes. We are dedicated to building an environment where everyone thrives. We have a culture of collaboration, ownership, and authenticity. We are proud to have built an interdisciplinary team that embodies this culture.
.png)
.png)
.png)
Latest News
Shennon Biotechnologies presents latest results at the Society for Immunotherapy of Cancer (SITC) Conference
Read Article
Shennon Biotechnologies Raises $13M Seed Financing to Accelerate Immunotherapy Target Discovery with Proprietary Single-Cell Functional Screening Platform
Read Article
Immunotherapy biotech unstealths with $13M; Anti-infection candidate for CF passes safety trial
Read Article
Shennon Biotechnologies Raises $13M Seed Financing to Accelerate Immunotherapy Target Discovery with Proprietary Single-Cell Functional Screening Platform
Read Article
How a onetime VC came back to science to focus on finding better targets faster against cancer
Read Article
Work with Us to Cure the Uncurable
